Big Pharma Faces Revenue Loss from Patent Cliffs

Big pharma companies like J&J, Merck, and Bristol Myers Squibb are facing patent cliffs that will lead to billions of dollars in revenue loss between now and 2030. To mitigate this, companies are focusing on building their drug pipelines, forming acquisitions, and partnerships. The impact of patent cliffs on companies varies depending on whether the drugs are small-molecule or biologic, with biosimilars posing challenges in market share acquisition. Despite the challenges, companies are expected to overcome the upcoming patent cliffs, with Merck's CEO anticipating over $20 billion in sales from oncology drugs by the mid-2030s.